Gotham Asset Management LLC Has $12.13 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Gotham Asset Management LLC grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,111 shares of the pharmaceutical company's stock after buying an additional 2,978 shares during the quarter. Gotham Asset Management LLC's holdings in Vertex Pharmaceuticals were worth $12,126,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. ABC Arbitrage SA bought a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $1,510,000. Czech National Bank boosted its holdings in shares of Vertex Pharmaceuticals by 6.2% in the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company's stock valued at $22,486,000 after buying an additional 3,260 shares during the last quarter. Highview Capital Management LLC DE grew its stake in shares of Vertex Pharmaceuticals by 1.8% in the fourth quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company's stock valued at $2,324,000 after buying an additional 102 shares in the last quarter. Davidson Investment Advisors increased its holdings in Vertex Pharmaceuticals by 26.0% during the fourth quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company's stock worth $24,630,000 after buying an additional 12,631 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its stake in shares of Vertex Pharmaceuticals by 75.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock worth $994,000 after purchasing an additional 1,062 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research analyst reports. Leerink Partners restated a "market perform" rating and issued a $503.00 price objective (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Piper Sandler decreased their price objective on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. Finally, HC Wainwright restated a "buy" rating and set a $550.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Thirteen research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $515.04.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX traded up $13.22 during mid-day trading on Thursday, hitting $434.38. 1,935,271 shares of the stock traded hands, compared to its average volume of 1,407,377. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The firm has a 50 day simple moving average of $485.28 and a two-hundred day simple moving average of $465.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The company has a market cap of $111.55 billion, a PE ratio of -197.45, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The business's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $4.76 earnings per share. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the sale, the executive vice president now owns 67,695 shares of the company's stock, valued at $30,805,286.70. The trade was a 0.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This represents a 10.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,005 shares of company stock worth $1,978,465. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.